Open-label Multicenter Phase 2 Study Evaluating the Efficacy & Safety of Daratumumab in Pediatric & Young Adult Subjects =1 & =30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Relapsed/refractory Precursor B-cell Or T-cell Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma
  • Age: Between 1 - 30 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Documented Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma 2. Second or greater relapse or refractory to 2 prior induction regimens for B-ALL 3. First or greater relapse or refractory to 1 prior induction/consolidation regimen for T-ALL

You may not be eligible for this study if the following are true:

  • 1. Received an allogeneic hematopoietic transplant within 3 months 2. Active acute graft-versus-host disease 3. Received immunosuppression post hematopoietic transplant within 1 month of study entry
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.